Evaluation of risk factors for the development of nephropathy in patients with IDDM: insertion/deletion angiotensin converting enzyme gene polymorphism, hypertension and metabolic control
Ursula Barnas(University of Vienna), Gert Mayer(University of Vienna), A. Illievich(University of Vienna), K Irsigler(Ludwig Boltzmann Institute for Cancer Research), Alice Schmidt, Dagmar Rabensteiner(Ludwig Boltzmann Institute for Cancer Research), Heidemarie Abrahamian, Alexandra Kaider, H. Kiener(University of Vienna), Rudolf Prager
Cited by 65
Related Papers
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
|The Lancet|2017|843
Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes
|The Lancet|1998|743
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
|The Lancet|2019|609
Erythropoietin Treatment of Anemia Associated with Multiple Myeloma
|New England Journal of Medicine|1990|450
Risk of pregnancy‐associated recurrent venous thromboembolism in women with a history of venous thrombosis
|Journal of Thrombosis and Haemostasis|2005|224